These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 23183522)

  • 1. Non-alcoholic steatohepatitis: the role of oxidized low-density lipoproteins.
    Walenbergh SM; Koek GH; Bieghs V; Shiri-Sverdlov R
    J Hepatol; 2013 Apr; 58(4):801-10. PubMed ID: 23183522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of liver disease with postprandial large intestinal triglyceride-rich lipoprotein accumulation and pro/antioxidant imbalance in normolipidemic non-alcoholic steatohepatitis.
    Musso G; Gambino R; De Michieli F; Biroli G; Fagà E; Pagano G; Cassader M
    Ann Med; 2008; 40(5):383-94. PubMed ID: 18484349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxidized LDL at the crossroads of immunity in non-alcoholic steatohepatitis.
    Houben T; Brandsma E; Walenbergh SMA; Hofker MH; Shiri-Sverdlov R
    Biochim Biophys Acta Mol Cell Biol Lipids; 2017 Apr; 1862(4):416-429. PubMed ID: 27472963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trapping of oxidized LDL in lysosomes of Kupffer cells is a trigger for hepatic inflammation.
    Bieghs V; Walenbergh SM; Hendrikx T; van Gorp PJ; Verheyen F; Olde Damink SW; Masclee AA; Koek GH; Hofker MH; Binder CJ; Shiri-Sverdlov R
    Liver Int; 2013 Aug; 33(7):1056-61. PubMed ID: 23617943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Redox balance in the pathogenesis of nonalcoholic fatty liver disease: mechanisms and therapeutic opportunities.
    Gambino R; Musso G; Cassader M
    Antioxid Redox Signal; 2011 Sep; 15(5):1325-65. PubMed ID: 20969475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrahepatic cholesterol influences progression, inhibition and reversal of non-alcoholic steatohepatitis in hyperlipidemic mice.
    Wouters K; van Bilsen M; van Gorp PJ; Bieghs V; Lütjohann D; Kerksiek A; Staels B; Hofker MH; Shiri-Sverdlov R
    FEBS Lett; 2010 Mar; 584(5):1001-5. PubMed ID: 20114046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammation in nonalcoholic steatohepatitis.
    Harmon RC; Tiniakos DG; Argo CK
    Expert Rev Gastroenterol Hepatol; 2011 Apr; 5(2):189-200. PubMed ID: 21476914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis.
    Larter CZ; Yeh MM; Van Rooyen DM; Brooling J; Ghatora K; Farrell GC
    J Gastroenterol Hepatol; 2012 Feb; 27(2):341-50. PubMed ID: 21929649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Rabbit model for the study of human NASH].
    Otogawa K; Kawada N
    Nihon Rinsho; 2006 Jun; 64(6):1043-7. PubMed ID: 16768107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic lipid metabolism and non-alcoholic fatty liver disease.
    Tessari P; Coracina A; Cosma A; Tiengo A
    Nutr Metab Cardiovasc Dis; 2009 May; 19(4):291-302. PubMed ID: 19359149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Roles of adipose restriction and metabolic factors in progression of steatosis to steatohepatitis in obese, diabetic mice.
    Larter CZ; Yeh MM; Van Rooyen DM; Teoh NC; Brooling J; Hou JY; Williams J; Clyne M; Nolan CJ; Farrell GC
    J Gastroenterol Hepatol; 2009 Oct; 24(10):1658-68. PubMed ID: 19788606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of microsomal triglyceride transfer protein in nonalcoholic steatohepatitis in novel spontaneous mouse model.
    Shindo N; Fujisawa T; Sugimoto K; Nojima K; Oze-Fukai A; Yoshikawa Y; Wang X; Yasuda O; Ikegami H; Rakugi H
    J Hepatol; 2010 Jun; 52(6):903-12. PubMed ID: 20392512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological IKK2 inhibition blocks liver steatosis and initiation of non-alcoholic steatohepatitis.
    Beraza N; Malato Y; Vander Borght S; Liedtke C; Wasmuth HE; Dreano M; de Vos R; Roskams T; Trautwein C
    Gut; 2008 May; 57(5):655-63. PubMed ID: 18408102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
    Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
    Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SREBP-2: a link between insulin resistance, hepatic cholesterol, and inflammation in NASH.
    Van Rooyen DM; Farrell GC
    J Gastroenterol Hepatol; 2011 May; 26(5):789-92. PubMed ID: 21488942
    [No Abstract]   [Full Text] [Related]  

  • 16. Possible involvement and the mechanisms of excess trans-fatty acid consumption in severe NAFLD in mice.
    Obara N; Fukushima K; Ueno Y; Wakui Y; Kimura O; Tamai K; Kakazu E; Inoue J; Kondo Y; Ogawa N; Sato K; Tsuduki T; Ishida K; Shimosegawa T
    J Hepatol; 2010 Aug; 53(2):326-34. PubMed ID: 20462650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxic lipids stored by Kupffer cells correlates with their pro-inflammatory phenotype at an early stage of steatohepatitis.
    Leroux A; Ferrere G; Godie V; Cailleux F; Renoud ML; Gaudin F; Naveau S; Prévot S; Makhzami S; Perlemuter G; Cassard-Doulcier AM
    J Hepatol; 2012 Jul; 57(1):141-9. PubMed ID: 22425624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tranilast, an antifibrogenic agent, ameliorates a dietary rat model of nonalcoholic steatohepatitis.
    Uno M; Kurita S; Misu H; Ando H; Ota T; Matsuzawa-Nagata N; Kita Y; Nabemoto S; Akahori H; Zen Y; Nakanuma Y; Kaneko S; Takamura T
    Hepatology; 2008 Jul; 48(1):109-18. PubMed ID: 18571789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Internalization of modified lipids by CD36 and SR-A leads to hepatic inflammation and lysosomal cholesterol storage in Kupffer cells.
    Bieghs V; Verheyen F; van Gorp PJ; Hendrikx T; Wouters K; Lütjohann D; Gijbels MJ; Febbraio M; Binder CJ; Hofker MH; Shiri-Sverdlov R
    PLoS One; 2012; 7(3):e34378. PubMed ID: 22470565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A fresh look at NASH pathogenesis. Part 1: the metabolic movers.
    Larter CZ; Chitturi S; Heydet D; Farrell GC
    J Gastroenterol Hepatol; 2010 Apr; 25(4):672-90. PubMed ID: 20492324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.